聚ADP核糖聚合酶
PARP抑制剂
化学
NAD+激酶
结合位点
烟酰胺
核糖
氢键
立体化学
组合化学
计算生物学
生物化学
酶
生物
聚合酶
分子
有机化学
出处
期刊:Cancer drug discovery and develogment
日期:2015-01-01
卷期号:: 205-221
标识
DOI:10.1007/978-3-319-14151-0_8
摘要
This chapter will roughly follow the evolution of NAD+mimetic, catalytic-site PARP inhibitor designs aided by the use of co-crystal structures and modeling. Early co-crystal structures of the PARP catalytic domain (CD) established a well-defined and well-conserved hydrogen bonding motif at the nicotinamide binding site with the carboxamide functionality of the inhibitor, and multiple pi-type interactions between the inhibitor and catalytic site tyrosine residues. Larger PARP inhibitors have demonstrated extended binding into the adenine-ribose site. The structure based drug design (SBDD) and modeling initially focused on PARP-1 (ARTD1) and PARP-2 (ARTD2), and these are the most well described proteins in the literature. Other PARP CDs have recently been crystallized, and SBDD efforts towards tankyrase 1 (TNKS1, ARTD5) and 2 (TNKS2, ARDT6) inhibitors will be described.
科研通智能强力驱动
Strongly Powered by AbleSci AI